Search

everythinglearnresearchcommunity

for

Search:↓

Intradermal botulinum toxin (BTX) injections effectively treat androgenetic alopecia (AGA) by inhibiting TGF-β1 secretion from hair follicles. Further research and long-term follow-up are needed to confirm these findings.

The conversation discusses experiences with NMN supplementation for hair growth, with some users reporting increased hair growth activity and others seeing no significant changes. OP has been using dutasteride and oral minoxidil, and recently added NMN, noticing increased shedding, which they hope indicates new hair growth.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation is about adding a low dose of pyrilutamide to a hair loss treatment regimen. Specific treatments mentioned include Minoxidil, finasteride, and RU58841.

User tried various hair loss treatments, now switching to Dut and hair transplant. Experienced side effects and plans to track them.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The user has been using oral finasteride, topical minoxidil, and tretinoin cream for hair loss, with positive progress noted after six months. They are advised to continue their current regimen and consider additional treatments like derma rolling, while being cautious about switching to dutasteride due to potential side effects.

The user is experiencing hair thinning despite using finasteride and minoxidil with added tretinoin, and is considering switching to dutasteride. Suggestions include trying dutasteride, oral minoxidil, microneedling, and possibly a hair transplant for better results.

Clascoterone 5% shows promising hair growth results but is criticized for high cost and unclear effectiveness compared to other treatments like finasteride. Glenmark is testing a combination of Clascoterone 7.5% and Minoxidil 5% in India.

The user experiences scalp itchiness despite using ketoconazole shampoo and is also taking oral finasteride and minoxidil. Suggestions include trying different shampoos like Head & Shoulders, using salicylic acid products, considering allergies, and consulting a dermatologist for alternatives like Ciclopirox.

The user is frustrated with minimal hair regrowth after using dutasteride, oral minoxidil, and previously finasteride and topical minoxidil. Despite feeling discouraged, others suggest continuing treatment as progress can be slow and subtle, with some users noting visible improvement.

Using PP405 and Clascoterone after a hair transplant may not cause issues if the transplant didn't achieve native density, but could lead to competition for blood supply if it did. Some users suggest waiting for these drugs to be available, as they might not significantly impact blood supply or regrowth.

The conversation is about a user seeking advice on adding GHK-Cu to RU58841 for hair loss treatment, while already using oral minoxidil, dutasteride, ketoconazole shampoo, and considering LLLT. They are unsure about the concentration and carrier solution for GHK-Cu.

Kintor is producing a cosmetic with KX826, starting at 0.5% concentration and moving to 1%. The 0.5% concentration wasn't as effective as minoxidil and finasteride, but the 1% concentration shows promise.

A user shared their positive experience with a hair transplant performed by Dr. Timothy Carman, using 1100 grafts via FUT surgery, and reported satisfaction with the results and minimal scarring. The user continues to use minoxidil and finasteride for hair maintenance.

Alfatradiol is discussed as a weak 5ARI and estrogen, not as effective as minoxidil, RU58841, or CB-03-01, but a safe alternative for those who can't use finasteride. Users express frustration over the lack of strong FDA-approved topical antiandrogens for hair loss.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

A 30-year-old with Norwood 3V hair loss uses finasteride 1.25 mg every other day and Minoxidil (Regaine 5%) twice daily, experiencing no side effects with the current regimen. The front hairline remains unchanged, but the crown appears better in certain lighting.

The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.

A 43-year-old experienced gynecomastia after 20 years of taking dutasteride and 7.5mg oral minoxidil. Suggestions include consulting an endocrinologist, checking hormones, and considering Nolvadex or DIM supplements.

The user is experiencing an itchy scalp and acne while using oral dutasteride and minoxidil for hair loss. They are considering stopping minoxidil to see if symptoms improve and possibly switching to finasteride if needed.

Woman uses antiandrogens for hair thinning prevention, experiences severe dry eye with finasteride. Asks if dutasteride could be better despite potential for worse dry eye.

Fluridil was abandoned due to its weak effectiveness and low binding affinity to the androgen receptor, making it less competitive against DHT and testosterone. Users discuss its limited results compared to other treatments like pyrilutamide and RU58841.

A 23-year-old has been using finasteride, dutasteride, and spironolactone to combat hair loss and hormonal acne, with mixed results and concerns about side effects. The user is experimenting with spironolactone despite its potential risks, hoping for skin and body hair improvements.

The conversation discusses an extensive hair loss treatment regimen including dutasteride, GT20029, RU58841, pyrilutamide, minoxidil, microneedling, ketoconazole shampoo, and experimental compounds. The user humorously describes their approach as a comprehensive strategy to combat hair loss while maintaining hair growth.

Dutasteride tablets are less effective than softgel capsules because they require a fat-based environment for proper absorption. Softgel capsules, like Avodart, are designed to maximize bioavailability, while powdered tablets may result in significantly lower DHT suppression.

The user is using topical dutasteride, finasteride, minoxidil, and tretinoin but seeing no results or side effects. They also microneedle every two weeks but experience little bleeding, questioning if a thick scalp is preventing treatment effectiveness.

RU58841 slowed hair loss for a DUPA sufferer after other treatments like finasteride, dutasteride, and minoxidil failed. Some users reported side effects with RU58841, while others did not experience any.

GT20029 and CosmeRNA are both potential hair loss treatments; GT20029 breaks down the androgen receptor, while CosmeRNA prevents its production. Continuous use is needed, but less frequently than current treatments like Minoxidil and Finasteride.

Exploring the potential of latanoprost as a hair loss treatment in combination with minoxidil and finasteride.